Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formycon Shifts Strategy On US Lucentis Biosimilar

As First Patient Dosed In Ustekinumab Phase III Studies

Executive Summary

Formycon has announced a change of strategy for the FYB201 biosimilar ranibizumab candidate being developed with Bioeq. Both firms insist the change is “not expected to have any impact on the timing of the anticipated launch of FYB201 in the US and EU countries.”

You may also be interested in...



Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar

The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.

Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Formycon And Bioeq Offer Ranibizumab Update

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel